The American Cancer Society National Consortium for Cancer Screening and Care is an issue-focused, time-bound partnership dedicated to the acceleration of a national response to the COVID-19 pandemic in relation to its detrimental impact on our collective progress in cancer screening and care.

The American Cancer Society National Consortium for Cancer Screening and Care is an issue-focused, time-bound partnership dedicated to the acceleration of a national response to the COVID-19 pandemic in relation to its detrimental impact on our collective progress in cancer screening and care.

United In Recovery and Improvement

The American Cancer Society National Consortium for Cancer Screening and Care is guided by action-oriented goal statements that promote the urgency of our collective response and opportunity. Over the course of 2021, we addressed each of these goal statements through a consensus-building cycle to create recommendations that aim to not only accelerate our recovery from the pandemic but also to build resilience and improve the nation's ability to provide quality cancer screening and care for all.

Accelerate

Accelerate responses to long-standing and emerging barriers to cancer screening and care.
Strengthen

Strengthen preparedness, infrastructure, and partnerships to minimize disruptions and address inequities.
Mobilize

Mobilize around sustained, coordinated commitments to promote cancer screening and care as a public health priority and improve the long-term effectiveness of screening programs.
Consensus Recommendations

These nine recommendations inform a national response and improvement plan for cancer screening and care.

About the ACS National Consortium

Members

The ACS National Consortium members represent a diverse, multi-sectored, and influential cohort of voices relentlessly dedicated to the safe and equitable recovery of cancer screening and treatment services.  See More > 

Resources and Reports

Find the latest resources and reports related to the ACS National Consortium’s work.  See More > 

© Copyright 2021 American Cancer Society, Inc. | Back to top ↑

The ACS’s enterprise-wide screening initiative, of which the National Consortium is a core component, is supported by generous sponsors including founding sponsor, Genentech, a member of the Roche Group alongside National Football League, Merck (known as MSD outside the United States and Canada), Novartis Oncology, Pfizer Oncology, BD (Becton, Dickinson and Company), Bristol-Myers Squibb, Intuitive, McKesson, AmerisourceBergen, Amgen, Roche Diagnostics and Regeneron/Sanofi-Genzyme.